Connect Biopharma (CNTB) vs Cue Biopharma (CUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cue Biopharma (CUE) has outperformed Connect Biopharma (CNTB) over the past year, losing 76.8% versus a loss of 80.6%. Over five years, CNTB leads with a -86.9% price change compared with -98.9% for CUE. Connect Biopharma is the larger company by market cap ($38.0 million vs $34.7 million), about 1.1 times the size, while Cue Biopharma is growing revenue faster (+195.7% vs -99.8%).
Cue Biopharma converts more of its revenue into profit, with a net margin of -96.9% versus -86687.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | CUE |
|---|---|---|
| Share price | $0.59 | $4.15 |
| Market cap | $38.05M | $34.69M |
| 1-day change | -6.08% | -7.78% |
| YTD return | -79.08% | -54.64% |
| 1-year return | -80.59% | -76.75% |
| 5-year return | -86.89% | -98.92% |
| EPS (TTM) | $-1.14 | $-27.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $64.00K | $27.47M |
| Revenue growth (YoY) | -99.75% | +195.75% |
| Net income (latest FY) | $-55.48M | $-26.60M |
| Operating margin | -90740.63% | -96.67% |
| Net margin | -86687.50% | -96.85% |
| 52-week high | $3.82 | $45.50 |
| 52-week low | $0.55 | $2.83 |
| Distance from 52-week high | -84.55% | -90.88% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +896.61% | +2020.48% |
| Average volume | 3.98M | 567.02K |
| Shares outstanding | 64.49M | 8.36M |
| Employees | 64 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cue Biopharma is more profitable, keeping -96.9 cents of every revenue dollar as net income versus -86687.5 cents for Connect Biopharma.
- Cue Biopharma grew revenue faster in its latest fiscal year (+195.75% vs -99.75%).
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
CNTB vs CUE FAQ
Which is bigger, Connect Biopharma or Cue Biopharma?
Connect Biopharma (CNTB) is larger, with a market capitalization of $38.05M compared with $34.69M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CNTB or CUE?
CUE returned -76.75% over the past 12 months, compared with -80.59% for CNTB (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Cue Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.